Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study.

"LG has participated or is participating as an investigator in clinical trials for AstraZeneca, MSD and Novartis, and hereby declares receipt of a research grant or consultancy fees from AstraZeneca, Chiesi, GlaxoSmithKline, Novartis and Sanofi-Regeneron. He also declares receipt of consultancy fees from Bayer, MSD and outside the submitted work. AC is an employee of AstraZeneca. CN declares receipt of consultancy fees from declares AstraZeneca, GSK, Sanofi, Chiesi, Novartis, ALK, Boehringer Ingelheim, Menarini and Mundipharma. SF declares receipt of consultancy fees from AstraZeneca, Sanofi, GlaxoSmithKline and Novartis. FR declares receipt of consultancy fees from GSK, Chiesi and AstraZeneca. NK has participated or is participating as an investigator in clinical trials for GlaxoSmithKline, Chiesi and Sanofi, and declares receipt of consultancy fees from AstraZeneca, Chiesi, GlaxoSmithKline, Sanofi and Novartis. CD declares receipt of consultancy fees from AstraZeneca, Sanofi, Chiesi, GlaxoSmithKline and Novartis. WG declares receipt of consultancy fees from AstraZeneca, Sanofi, Chiesi, GlaxoSmithKline and Novartis. NJ declares receipt of consultancy fees from Chiesi, AstraZeneca, GlaxoSmithKline. JM declares receipt of consultancy fees from AstraZeneca and non-financial support from ALK-Abello, Menarini, GSK, Boehringer-Ingelheim, Chiesi, Astra-Zeneca, Sanofi, Novartis, Stallergènes, Vitalaire, LVL Arard and AJR médical. CL declares receipt of consultancy fees or non-financial support from AstraZeneca, Sanofi, Novartis, Boehringer Ingelheim, Chiesi, GSK, Menarini, Asten, France Oxygène, SOS oxygène. AP declares receipt of consultancy fees from AstraZeneca, GSK, Chiesi, Novartis, Menarini, Sanofi. AB declares receipt of consultancy fees from Sanofi and AstraZeneca. CT declares research grants or receipt of consultancy fees from AstraZeneca, Sanofi, GlaxoSmithKline and Novartis. AD declares receipt of consultancy fees from ALK, AstraZeneca, Chiesi, GlaxoSmithKline, Menarini, Novartis, Sanofi and Zambon. The other co-authors declare no conflict of interests."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: AstraZeneca provided institutional financial support for this study."

"Ethics approval and consent to participate: The study protocol registered (ANSM RCB ID: 2020 A00431 38) was approved in April 2020 by the French Ethics Committee, CPP Est II, ref. CNRIPH 20.02.14.60526. The trial was conducted in accordance with Good Clinical Practices and the French Data Protection Authority (No. 2038025). Participants gave consent to participate."